PMID- 35850844
OWN - NLM
STAT- MEDLINE
DCOM- 20220720
LR  - 20220720
IS  - 1001-5302 (Print)
IS  - 1001-5302 (Linking)
VI  - 47
IP  - 14
DP  - 2022 Jul
TI  - [Mechanism of Liangfu Pills in treatment of functional dyspepsia: based on 
      network pharmacology and experimental verification].
PG  - 3853-3862
LID - 10.19540/j.cnki.cjcmm.20211230.705 [doi]
AB  - This study aims to explore the potential mechanism of Liangfu Pills in the 
      treatment of functional dyspepsia(FD) based on network pharmacology and molecular 
      docking, and verify the mechanism by animal experiment. The active components of 
      Liangfu Pills were screened from Traditional Chinese Medicine Systems 
      Pharmacology Database and Analysis Platform(TCMSP), and the targets of Liangfu 
      Pills were predicted by SwissTargetPrediction. The targets of FD were retrieved 
      from GeneCards. On this basis, the common targets of the disease and the pills 
      were yielded and the protein interaction was retrieved based on STRING. The core 
      targets were screened out, followed by Gene Oncology(GO) term enrichment and 
      Kyoto Encyclopedia of Genes and Genomes(KEGG) pathway enrichment analysis with 
      DAVID. Finally, molecular docking was carried out with the help of AutoDock Tools 
      to predict the binding degree between the effective components of Liangfu Pills 
      and core targets. A total of 19 active components of Liangfu Pills and 591 
      FD-related targets were screened out by network pharmacology, of which 253 were 
      common targets of the disease and the prescription. Liangfu Pills was mainly 
      involved in the biological processes of response to drug, negative regulation of 
      transcription, positive regulation of apoptotic process, and cell surface 
      receptor signaling pathway, and the KEGG pathways of hypoxia-inducible 
      factor-1(HIF-1) signaling pathway, serotonergic synapse, tumor necrosis 
      factor(TNF) signaling pathway, cyclic adenosine monophosphate(cAMP) signaling 
      pathway, calcium signal pathway, and inflammatory mediator regulation of 
      transient receptor potential(TRP) channels. The results of molecular docking 
      showed that the key active components of Liangfu Pills had certain binding 
      activity to the targets mitogen-activated protein kinase 1(MAPK1), protein kinase 
      B(AKT1), transient receptor potential cation channel subfamily V member 1(TRPV1), 
      5-hydroxytryptamine receptor 1 A(HTR1 A), and 5-hydroxytryptamine receptor 2 
      A(HTR2 A). FD was induced in rats, and then Liangfu Pills was given to FD rats 
      for 7 days. The results showed that Liangfu Pills could significantly relieve the 
      symptoms of FD rats, significantly increase the expression of 
      5-hydroxytryptamine(5-HT), and down-regulate the expression of TRPV1. Through 
      network pharmacology, molecular docking, and experimental verification, this 
      study proved that Liangfu Pills improved FD through multiple components and 
      multiple targets. The result lays a basis for further research on the mechanism 
      and clinical application of Liangfu Pills in the treatment of FD.
FAU - He, Jie-Ying
AU  - He JY
AD  - School of Traditional Chinese Medicine, Guangdong Pharmaceutical University 
      Guangzhou 510006, China.
FAU - Gui, Bei
AU  - Gui B
AD  - School of Traditional Chinese Medicine, Guangdong Pharmaceutical University 
      Guangzhou 510006, China.
FAU - Chen, Yan-Fen
AU  - Chen YF
AD  - School of Traditional Chinese Medicine, Guangdong Pharmaceutical University 
      Guangzhou 510006, China.
FAU - Yin, Yong-Qin
AU  - Yin YQ
AD  - School of Traditional Chinese Medicine, Guangdong Pharmaceutical University 
      Guangzhou 510006, China.
FAU - Tao, Shu-Hong
AU  - Tao SH
AD  - School of Traditional Chinese Medicine, Guangdong Pharmaceutical University 
      Guangzhou 510006, China.
FAU - Shen, Zhi-Bin
AU  - Shen ZB
AD  - School of Traditional Chinese Medicine, Guangdong Pharmaceutical University 
      Guangzhou 510006, China.
FAU - Li, Kun-Ping
AU  - Li KP
AD  - Institute of Traditional Chinese Medicine, Guangdong Pharmaceutical University 
      Guangzhou 510006, China.
FAU - Fu, Jiang-Bo
AU  - Fu JB
AD  - School of Traditional Chinese Medicine, Guangdong Pharmaceutical University 
      Guangzhou 510006, China.
FAU - Wei, Ling
AU  - Wei L
AD  - School of Traditional Chinese Medicine, Guangdong Pharmaceutical University 
      Guangzhou 510006, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhongguo Zhong Yao Za Zhi
JT  - Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese 
      materia medica
JID - 8913656
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - Animals
MH  - *Drugs, Chinese Herbal/chemistry/pharmacology/therapeutic use
MH  - *Dyspepsia/drug therapy
MH  - Medicine, Chinese Traditional
MH  - Molecular Docking Simulation
MH  - Network Pharmacology
MH  - Rats
OTO - NOTNLM
OT  - Liangfu Pills
OT  - action mechanism
OT  - animal experiment
OT  - functional dyspepsia
OT  - molecular docking
OT  - network pharmacology
EDAT- 2022/07/20 06:00
MHDA- 2022/07/22 06:00
CRDT- 2022/07/19 07:49
PHST- 2022/07/19 07:49 [entrez]
PHST- 2022/07/20 06:00 [pubmed]
PHST- 2022/07/22 06:00 [medline]
AID - 10.19540/j.cnki.cjcmm.20211230.705 [doi]
PST - ppublish
SO  - Zhongguo Zhong Yao Za Zhi. 2022 Jul;47(14):3853-3862. doi: 
      10.19540/j.cnki.cjcmm.20211230.705.